Ado-trastuzumab emtansine (T-DM1) in HER2+ advanced breast cancer patients: does pretreatment with pertuzumab matter?

Alessandra Fabi, Diana Giannarelli, Luca Moscetti, Daniele Santini, Alberto Zambelli, Michelino De Laurentiis, Michele Caruso, Daniele Generali, Enrichetta Valle, Vita Leonardi, Katia Cannita, Grazia Arpino, Gianfranco Filippelli, Gianluigi Ferretti, Marianna Giampaglia, Filippo Montemurro, Cecilia Nistico, Simona Gasparro, Francesco Cognetti

Research output: Contribution to journalArticlepeer-review

Abstract

AIM: We evaluated the outcomes of patients treated with ado-trastuzumab emantasine (T-DM1) after first-line pertuzumab/trastuzumab, compared with those receiving a trastuzumab-only-based regimen. PATIENTS & METHODS: Patients who received second-line T-DM1 after pertuzumab/trastuzumab (n = 34) were compared with those who received only trastuzumab (n = 73). RESULTS: Overall response rate was 33.3% in patients with prior pertuzumab and 57.1% in the remaining subjects. Disease control rate was 47 and 43%, respectively, and the clinical benefit rate was 43.3 and 71.1%, respectively. Median progression-free survival was 5.0 and 11.0 months, respectively (hazard ratio: 2.02; 95% CI: 1.14-3.58; p = 0.01). CONCLUSION: Patients treated with T-DM1 who previously received pertuzumab present poorer clinical outcomes compared with those receiving a trastuzumab-only-based regimen in the first-line setting.
Original languageEnglish
Pages (from-to)2791-2797
Number of pages7
JournalFuture Oncology
Volume13
Publication statusPublished - Dec 1 2017

Keywords

  • HER2 second-line, HER2-positive tumors, T-DM1, metastatic breast cancer, pertuzumab

Fingerprint Dive into the research topics of 'Ado-trastuzumab emtansine (T-DM1) in HER2+ advanced breast cancer patients: does pretreatment with pertuzumab matter?'. Together they form a unique fingerprint.

Cite this